Multikinase inhibitor-induced rash is very common. It occurs in 20–30% of patients on sorafenib, regorafenib or imatinib therapy, 10–20% of patients on sunitinib, and 5–10% of those on pazopanib therapy. It arises during the first 6–8 weeks of treatment and consists of mild eruptions ...